UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063674
Receipt number R000072701
Scientific Title Fixed very-low-dose oral immunotherapy using a standardized food product for children with severe peanut, walnut or cashew allergy
Date of disclosure of the study information 2026/11/20
Last modified on 2026/11/18 11:18:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Fixed very-low-dose oral immunotherapy using a standardized food product for children with severe peanut, walnut or cashew allergy

Acronym

Fixed very-low-dose oral immunotherapy for children with severe peanut, walnut or cashew allergy

Scientific Title

Fixed very-low-dose oral immunotherapy using a standardized food product for children with severe peanut, walnut or cashew allergy

Scientific Title:Acronym

Fixed very-low-dose oral immunotherapy for children with severe peanut, walnut or cashew allergy

Region

Japan


Condition

Condition

Food allergy

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to compare the proportion of children with severe peanut, walnut, or cashew allergy who achieve short-term unresponsiveness (STU) to 0.5 g of the respective allergen after a 2-week avoidance period, following 12 months of fixed very-low-dose oral immunotherapy (OIT) administered either daily or twice weekly.

Basic objectives2

Others

Basic objectives -Others

As a secondary objective, this study aims to compare the safety and adherence of fixed very-low-dose oral immunotherapy (OIT) between the daily and twice-weekly administration groups.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The proportion of patients who achieve short-term unresponsiveness (STU), defined as the ability to consume the entire 0.5 g dose of the target allergenic food without developing allergic symptoms during an oral food challenge (OFC) performed after a 2-week avoidance period, 12 months after the initiation of the intervention.

Key secondary outcomes

Frequency and severity of adverse reaction during home ingestion.
Changes in allergen-specific IgE and IgG4 levels at baseline and months 1, 3, 6, and 12.
The positive rate of the baseline 0.02 g OFC among provisionally enrolled patients, as well as the characteristics and severity of allergic reactions, treatments required, age, sex, and allergen-specific IgE and IgG4 levels.
Adherence to study-product ingestion assessed by participant diaries.
STU rates after 12 months for each culprit food (peanut, walnut, and cashew).


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Dose comparison

Stratification


Dynamic allocation

YES

Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Daily group: Participants eat consuming one unit of the standardized food product containing 0.02 g of the culprit food (peanut, walnut, and cashew) once daily at home from the following day for 12 months.

Interventions/Control_2

Twice-weekly group: Participants eat consuming one unit of the standardized food product containing 0.02 g of the culprit food (peanut, walnut, and cashew) twice weekly at home from the following day for 12 months.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

3 years-old <=

Age-upper limit

18 years-old >

Gender

Male and Female

Key inclusion criteria

Patients with a positive OFC to 0.5 g or less of peanut, walnut, or cashew (one culprit food per participant, even if more than one qualifies), ability to undergo a 0.02g OFC within one year after the qualifying OFC and written informed consent from a legally authorized representative, or from the participant and representative, as applicable. Only participants with a negative baseline 0.02g OFC proceed to full registration and randomization.

Key exclusion criteria

Poorly controlled asthma (Childhood Asthma Control Test [C-ACT] or Asthma Control Test [ACT] score <= 19)
Severe atopic dermatitis (Eczema Area and Severity Index [EASI] score >= 16)
Treatment with a biologic agent, systemic Janus kinase (JAK) inhibitor, systemic corticosteroid, or immunosuppressant
Concomitant immune-related disease, including autoimmune disease, immune-complex disease, or immunodeficiency
Any other condition judged by the investigator to make participation inappropriate

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Noriyuki
Middle name
Last name Yanagida

Organization

National Hospital Organization Sagamihara National Hospital

Division name

Department of pediatrics

Zip code

252-0392

Address

18-1, Sakuradai, Minamiku, Sagamihara City, Kanagawa, Japan

TEL

042-742-8311

Email

k.nagakura@foodallergy.jp


Public contact

Name of contact person

1st name Ken-ichi
Middle name
Last name Nagakura

Organization

National Hospital Organization Sagamihara National Hospital

Division name

Department of pediatrics

Zip code

252-0392

Address

18-1, Sakuradai, Minamiku, Sagamihara City, Kanagawa, Japan

TEL

042-742-8311

Homepage URL


Email

k.nagakura@foodallergy.jp


Sponsor or person

Institute

National Hospital Organization Sagamihara National Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Sagamihara National Hospital

Address

18-1, Sakuradai, Minamiku, Sagamihara City, Kanagawa, Japan

Tel

042-742-8311

Email

makino.megumi.bn@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2026 Year 10 Month 20 Day

Date of IRB

2026 Year 10 Month 20 Day

Anticipated trial start date

2026 Year 11 Month 11 Day

Last follow-up date

2029 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 18 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072701